Kringle Pharma,Inc. Logo

Kringle Pharma,Inc.

Develops regenerative HGF medicines for rare and intractable neurological diseases.

4884 | T

Overview

Corporate Details

ISIN(s):
JP3270790003
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号彩都バイオインキュベータ207号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable diseases. Originating as a university spin-off, the company's core strength is its proprietary platform for manufacturing pharmaceutical-grade recombinant human Hepatocyte Growth Factor (HGF). HGF is an endogenous protein with protective, regenerative, and tissue-repairing functions. Kringle Pharma is advancing its HGF drug candidates through clinical trials for several conditions, including rare and neurological diseases such as spinal cord injury and Amyotrophic Lateral Sclerosis (ALS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-16 09:00
Registration Form
有価証券届出書(組込方式)
Japanese 364.6 KB
2025-05-12 08:41
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-05-12 08:40
Interim Report
半期報告書-第24期(2024/10/01-2025/09/30)
Japanese 181.3 KB
2024-12-23 06:32
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-12-23 06:31
Registration Form
確認書
Japanese 8.2 KB
2024-12-23 06:30
Annual Report
有価証券報告書-第23期(2023/10/01-2024/09/30)
Japanese 2.2 MB
2024-12-23 06:30
Governance Information
内部統制報告書-第23期(2023/10/01-2024/09/30)
Japanese 21.7 KB
2024-08-26 03:25
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-05-13 08:40
Quarterly Report
四半期報告書-第23期第2四半期(2024/01/01-2024/03/31)
Japanese 179.6 KB
2024-05-13 08:40
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-09 07:41
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-09 07:40
Quarterly Report
四半期報告書-第23期第1四半期(2023/10/01-2023/12/31)
Japanese 139.3 KB
2023-12-25 08:24
Post-Annual General Meeting Information
臨時報告書
Japanese 22.3 KB
2023-12-25 08:23
Registration Form
確認書
Japanese 8.2 KB
2023-12-25 08:22
Governance Information
内部統制報告書-第22期(2022/10/01-2023/09/30)
Japanese 21.6 KB

Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kringle Pharma,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea
188260
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France
SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan
4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland
SANN
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.